A 30-second cavity treatment stops toddler decay, and turns the treated tooth black

A cavity treatment that takes seconds, skips the drill and the Novocain, and turns the treated spot permanently black stopped decay in more than half of treated baby teeth in a University of Michigan Phase III trial of 830 children under 6, published Tuesday in JAMA Pediatrics.

In the trial, 830 children under 6 received silver diamine fluoride (SDF), a low-cost liquid brushed directly onto a cavity with a small sponge-tipped applicator. Reapplied every six months, SDF stopped decay in more than half of the affected baby teeth. The trial recruited participants from dental offices, pediatric medical practices, and Head Start and Early Head Start programs in Michigan, New York, and Iowa, and reported no serious adverse events tied to the treatment. JAMA Pediatrics

SDF is a small molecule of silver, ammonia, and fluoride first developed in Japan in the 1960s. The silver kills the bacteria breaking down the tooth; the fluoride hardens what is left. The treatment does not fill the hole. A tooth that has already lost enamel and dentin still has that cavity, and the stain is permanent. For a toddler who cannot sit still for a filling, or whose family cannot afford one, the trade-off is the point: pain stops, infection risk drops, and the visit takes seconds.

The black stain is also the most common reason parents decline. "It's a great treatment, but it's not for everybody," said Margherita Fontana in an NIH release on the trial. The cosmetic effect is not a side effect so much as the visible signature of the chemistry: silver deposits turn the decayed area dark on contact and stay that way.

SDF has been used in dozens of countries for decades. It has been used off-label since 2014, when the FDA cleared it as a medical device for reducing tooth sensitivity, not for arresting decay. That classification is why most U.S. insurers do not routinely reimburse it, why some pediatric dental offices do not stock it, and why parents who want it usually have to ask. Routine use in the U.S. is concentrated in safety-net clinics, dental schools, and a subset of pediatric practices that have built reimbursement and consent workflows around it.

The 830-patient U.S. Phase III gives a sponsor the data they would need to file for FDA relabeling of SDF as a drug for tooth decay rather than as a device for sensitivity. Approval on that pathway would not change how the liquid works; it would change who pays for it. Reimbursement would follow, and the treatment would move from an off-label option a parent has to chase down to a routine part of pediatric dental care, with the dark-staining trade-off disclosed in consent forms rather than negotiated after the fact.

Untreated cavities send thousands of young U.S. children to emergency departments each year, and most of those visits end with antibiotics and a referral rather than a repair. A 30-second brush-on that stops a cavity from getting worse is a real option for that population, with one caveat a parent needs to see before saying yes: the dark spot does not come off.